VKORC1和CYP2C9基因多态性对ICU患者华法林抗凝治疗的指导价值

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (955 KB) HTML (0 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the guiding value of vitamin K epoxide reductase complex subunit 1 (VKORC1) and cytochrome oxidase P450 2C9 (CYP2C9) gene polymorphism detection on anticoagulation therapy of warfarin in intensive care unit (ICU) patients. Methods Ninety patients with indication of anticoagulation (atrial fibrillation, deep vein thrombosis and pulmonary embolism) admitted to ICU of Characteristics Medical Center of PLA Rocket Force from June 2019 to June 2023 were retrospectively analyzed. The study group (30 cases) underwent genetic testing and were instructed to use warfarin based on the test results, while the control group (60 cases) implemented the conventional clinical warfarin medication strategy without genetic testing. Both groups were followed up for 6 months. The general clinical data, genotype distribution of the study group, INR attainment time, time in treatment range TTR, warfarin starting dose, maintenance dose, incidence of bleeding events and incidence of INR ≥ 4.0 events were compared between the two groups. Results The time to achieve INR in the study group was (9.56±1.68) d, which was significantly shorter than that in the control group (11.12±2.03) d, P<0.05. The TTR in the study group was (72.56±6.90) %, which was higher than that in the control group (64.45±7.82) %, P<0.05. The starting and maintenance doses of warfarin in the study group were (2.91±0.73) mg/d and (3.17±0.81) mg/d, respectively, which were not statistically different from those in the control group (P>0.05). There were six cases (20.00%) of small bleeding events in the study group, which was significantly lower than that in the control group (twenty-seven cases, 45.00%, P<0.05). In contrast, there was no significant difference in the incidence of major bleeding events between the two groups (P>0.05). The incidence of INR≥4.0 in the study group was 16.67%, significantly lower than that in the control group (40.00%, P<0.05). Conclusions Detection of VKORC1 and CYP2C9 polymorphisms in ICU patients with indication of anticoagulation is beneficial to enhance anticoagulation efficacy, reduce related adverse reactions, and improve drug safety.

Key words： intensive care unit warfarin gene polymorphism CYP2C9 VKORC1 anticoagulation therapy

Received: 31 October 2023

ZTFLH:

R973

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YAN Bin
	ZHANG Mei
	ZHAO Guifeng

Cite this article:

YAN Bin,ZHANG Mei,ZHAO Guifeng. Guiding value of VKORC1 and CYP2C9 gene polymorphisms on anticoagulation treatment of warfarin in ICU patients[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2024, 35(10): 853-856.

URL:

https://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR https://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2024/V35/I10/853

[1]	叶碧玲, 林文基, 徐湛. ICU危重症患者炎性因子在心房纤颤患者中的水平变化分析[J]. 心血管病防治知识, 2021,11(5):14-16.
[2]	Johnson J A,Gong L,Whirl-Carrillo M,et al.Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing[J].Clin Pharmacol Ther, 2011,90(4):625-629.
[3]	Wu S,Chen X, Jin D Y, et al.Warfarin and vitamin K epoxide reductase: a molecular accounting for observed inhibition[J].Blood, 2018,132(6):647-657.
[4]	Flora D R,Rettie A E,Brundage R C, et al. CYP2C9 genotype-dependent warfarin pharmacokinetics: impact of CYP2C9 genotype on rand swarfarin and their oxidative metabolites[J].J Clin Pharmacol,2017,57(3):382-393.
[5]	Klein T E,Altman R B,Eriksson N,et al.Estimation of the warfarin dose with clinical and pharmacogenetic data[J].N Engl J Med,2009,360(8):753-764.
[6]	陈幽攸,任小群,杨探,等.基于CYP2C9与VKORC1基因多态性的心脏瓣膜置换术后华法林个体化给药剂量预测的3种模型算法比较[J].国际检验医学杂志,2021,42(4):439-443.
[7]	中南大学湘雅医院临床药理研究所,中南大学临床药理研究所,中南大学湘雅医学检验所.药物代谢酶和药物作用靶点基因检测技术指南(试行)概要[J].实用器官移植电子杂志, 2015,3(5):257-267.
[8]	McClain M R, Palomaki G E, Piper M,et al.A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding[J].Genet Med, 2008,10(2):89-98.
[9]	张莉,张磊,王娜,等.重症患者伴发深静脉血栓栓塞症使用低分子肝素抗凝治疗的抗-Xa因子活性达标率及影响因素分析[J].中国医院药学杂志,2023,43(10):1138-1142.
[10]	孙艺红.华法林抗凝治疗的中国专家共识[J].中华内科杂志, 2013, 52(1):76-82.
[11]	李世英,柳景华.欧美出血学术研究会(BARC)关于出血的统一定义[J].中国介入心脏病学杂志, 2012,20(4):231-234.
[12]	Gemmati D,Burini F,Talarico A,et al.The active metabolite of warfarin (3'-Hydroxywarfarin) and correlation with INR, warfarin and drug weekly dosage in patients under oral anticoagulant therapy: a pharmacogenetics study[J].PLoS One,2016,11(9):e0162084.
[13]	Tse G,Gong M, Li G,et al.Genotype-guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta-analysis of randomized controlled trials[J].Br J Clin Pharmacol,2018,84(9):1868-1882.
[14]	Arwood M J,Deng J,Drozda K,et al.Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: a proposal for a new pharmacogenetic dosing approach[J].Clin Pharmacol Ther,2017,101(5):675-683
[15]	刘芃菲,卓钟灵,苏明, 等.中国汉族人群CYP2C9及VKORC1基因多态性及其对华法林用药剂量的相关性研究[J].中华检验医学杂志, 2020(1):71-72.
[16]	丁维剑,汪亚南,苗仁华. CYP2C9和VKORC1基因多态性对华法林个体化用药的指导价值[J].实用心脑肺血管病杂志, 2021,29(12):121-124.
[17]	齐光照,薄惠,王维杰.中原地区汉族和回族中国人群CYP2C9~* 3、VKORC1-1639G>A和CYP4F2~* 3的遗传多态性[J].山西医科大学学报,2017,48(12):1265-1272.
[18]	宫小薇,袁雅冬,贡莹,等. CYP2C9、VKORC1基因多态性在PTE患者华法林抗凝治疗中的应用分析[J]. 医学综述,2021,27(14):2883-2887.